Opinion|Videos|June 1, 2026
Clinical Approaches for Treatment Intensification in Metastatic Castration-Sensitive Prostate Cancer
Fact checked by: Tracy Ann Politowicz
This episode reviews treatment intensification in metastatic castration-sensitive prostate cancer, focusing on why ADT plus an ARPI is the current backbone of care, what barriers still limit its use, and how clinicians think about triplet therapy, de-intensification, frail patients, and emerging biomarker-driven options such as PARP inhibitors.
Episodes in this series
This episode reviews treatment intensification in metastatic castration-sensitive prostate cancer, focusing on why androgen deprivation therapy (ADT) plus an androgen receptor pathway inhibitor (ARPI) is the current backbone of care, what barriers still limit its use, and how clinicians think about triplet therapy, deintensification, frail patients, and emerging biomarker-driven options such as PARP inhibitors.
Related Content
Latest CME
Trending on Urology Times
1
The ArteraAI Prostate Test: What It Is and How It Works
2
HHS requests testosterone therapy label updates, citing new safety data
3
Retrospective study suggests differences in OAB therapy persistence among older adults
4
FDA gives nod to feasibility study of NanoKnife IRE for benign prostatic hyperplasia
5